EVOCAL Health develops AI-driven voice analysis technologies designed to use speech as a predictive biomarker for health and disease. The company’s platform focuses on extracting clinically relevant signals from natural voice recordings to support digital diagnostics and therapeutic development. Its approach treats voice as a scalable, non-invasive source of biological data. EVOCAL Health positions its technology within clinical research and digital health rather than consumer wellness.

The technology analyzes acoustic, prosodic, and temporal features of speech that correlate with neurological and physiological states. Machine learning models are applied to identify patterns associated with disease risk, progression, or treatment response. These voice-derived biomarkers can be collected remotely and longitudinally, enabling continuous monitoring with minimal burden on patients. The platform emphasizes robustness across languages, contexts, and recording conditions.

EVOCAL Health targets applications across longevity research, neurodegenerative disease, and broader health monitoring. The platform is intended for use in clinical trials, digital diagnostics, and therapy development rather than standalone consumer products. Its focus reflects growing interest in voice as an accessible biomarker for tracking brain and systemic health over time.